Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A random controlled trail to evaluate the efficacy of migraine standard electroacupuncture formula, and to analysis the regulation of the intensity-effects and to observe the peripheral NO, CGRP and NF-кB expression level of migraine patients after electroacupuncture treatment.
acupuncture group(group A): treated by acupuncture for 20 days, 1 time per day control group(group B): treated by FlunarizineHydrochloride for 20 days, 1 table per day.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| electro-acupuncture | Experimental | 100hz, 2min. electro-acupoint: LI4(Large Intestine4) with LV3(Liver3).5times a week. lasting for 4 weeks. |
|
| routin medicine | Active Comparator | one tablet of flunarizine hydrochloride tablet per day. lasting for 20days |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| electro-acupuncture | Device | electro-acupuncture on acupoints according to the traditional syndrome diagnosis.once per day, for 20 days. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Migraine Disability Assessment Questionnaire (MIDAS) | a scientifically reliable and valid measure of migraine disability that can improve communication between patients and physicians, assess migraine severity and act as an outcome measure to monitor treatment efficacy | 20 days |
| Measure | Description | Time Frame |
|---|---|---|
| The medical outcomes study 36-item short-form health survey(SF-36) | A 36-item short-form (SF-36) was constructed to survey health status in the Medical Outcomes Study | 20 days |
| peripheral Nitrogen Monoxide(NO) protein expression |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jian Pei, Ph.D | Longhua Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Longhua Hospital,Shanghai University of Traditional Chinese Medicine | Shanghai | 200032 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008881 | Migraine Disorders |
| ID | Term |
|---|---|
| D051270 | Headache Disorders, Primary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D005444 | Flunarizine |
| ID | Term |
|---|---|
| D010879 | Piperazines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| flunarizine hydrochloride | Drug | flunarizine hydrochloride ，10mg/day，for 20 days。 |
|
|
marker
| 20 days |
| peripheral Calcitonin gene related peptide(CGRP) protein expression | marker | 20 days |
| peripheral Nuclear factor-kappa B(NF-кB) protein expression | marker | 20 days |
| Visual Analogue Scale (VAS) to assess pain | Visual Analogue Scale (VAS) were applied to measure pain in patients | 20 days |
| D009422 | Nervous System Diseases |